GTM Operations

Heidi secures $340M to turn its NHS AI scribe into a full clinical AI partner. September 23, 2026 * Heidi raised $340M - $100M in Series C equity and $240M in non-dilutive growth financing - at a $900M valuation, almost double its price eight months ago. * The AI scribe now supports 2.8 million patient interactions a week across 190 countries, and is the sole supplier for the NHS's largest-ever clinical AI documentation deal. * Annual recurring revenue jumped from $1 million to $50 million in two years, even as one of its two new checks lands from a fund that takes no equity at all. Heidi has raised $340 million as it pushes its AI Care Partner beyond note-taking and into the rest of a clinician's workday. The money comes in two pieces: a $100 million Series C led by Blackbird, with existing backers Phoenix Court, Point72 Private Investments and Headline also participating, and a separate $240 million growth investment from General Catalyst's Customer Value Fund. Only the first part is equity. The Series C values the Melbourne company at $900 million, nearly double the $465 million it carried eight months ago. "From the day I started Heidi, the ambition was always bigger than writing doctor's notes. I imagined AI sitting alongside clinicians throughout their work, from documenting consultations to helping carry out the work that follows them," said Dr Thomas Kelly, co-founder and chief executive of Heidi. Kelly, a former vascular surgical trainee, founded Heidi in Melbourne in 2021 with Waleed Mussa and Yu Liu. The platform started as ambient documentation and has since added Heidi Evidence, a point-of-care clinical guidance tool that has answered more than 10 million clinician queries since launching in March, alongside a wearable microphone (Remote) and a voice-to-text feature (Dictate). The NHS becomes the proving ground. The UK is now central to that expansion. Heidi was selected earlier this year as sole supplier for NHS England Midlands' clinical AI documentation framework, which it describes as the largest procurement of its kind in NHS history, covering 15 acute and community trusts, every integrated care board in the region and 1,239 GP practices. Heidi says its UK footprint has returned several million hours of clinical capacity back to frontline teams, though the company should confirm the latest figure before publication; its most recent published UK impact report put the number at just over four million hours. A crowded AI scribe market. Heidi isn't the only company chasing this. Tech Funding News recently covered Tandem Health's $100 million Series B, which pairs AI scribing with coding assistance and clinical decision support across European hospitals. Further down market, TFN reported on Mindoo's €5 million raise for configurable AI agents that handle hospital intake and follow-up communication rather than transcription alone. The direction of travel across the category is the same: from documenting care to acting on it. Heidi's answer is to build the compute-heavy pieces - transcription and note generation - almost entirely on its own models rather than licensing frontier ones, which the company says lets it tune accuracy, latency and cost task by task. "We are proud to continue backing Heidi and their mission to double the world's healthcare capacity and deliver relief to every clinician across the globe. The team's strong domain expertise and product - that clinicians deeply trust - make this ambition absolutely achievable," said Julia Svennerstål-Hawkins, general partner at Phoenix Court. The harder question now is whether a debt-like, revenue-share instrument like General Catalyst's becomes the template other AI-scribe companies use to scale sales without diluting founders, or whether it's a structure only companies with Heidi's growth economics can access.

Heidi receives $340 million for AI in healthcare. The health tech company is raising $100 million in a Series C round and an additional $240 million in growth financing. The equity round values Heidi at $900 million. News by Marc Nemitz · Berlin, 23. September 2026 The health tech scaleup Heidi is raising a total of $340 million in fresh capital to further expand its AI platform for healthcare professionals. Of that amount, $100 million comes from a Series C funding round led by Blackbird. An additional $240 million is being provided by General Catalyst's Customer Value Fund as growth financing. The Series C round values Heidi at $900 million. The company plans to use the capital to expand internationally, strengthen its presence in the DACH region, and increase investment in regulatory and clinical requirements for the European market. $100 million in equity plus growth funding. In addition to Blackbird, existing investors such as Phoenix Court - the investment firm behind LocalGlobe, Latitude, and Solar Funds - as well as Point72 Private Investments and Headline are participating in the Series C round. Together with the additional funding from General Catalyst, the transaction provides Heidi with $340 million. According to the company, it has raised a total of $436.6 million from investors to date. Heidi was founded in Melbourne, Australia, and is developing a so-called "AI Care Partner" designed to support healthcare professionals during their clinical workday. From documentation to clinical workflow. Heidi initially focused on AI-powered documentation of medical consultations. The company is now seeking to move beyond traditional scribe functions. The platform is designed to handle administrative tasks, provide clinical knowledge, and increasingly integrate with electronic health record systems. With "Evidenz," for example, Heidi offers a feature designed to provide context-specific medical information at the point of care. According to the company, nearly eight million requests have been processed since its launch in March 2026. In addition, the platform features a dictation function and "Remote," its own portable hardware device. For transcription and the creation of medical notes, Heidi states that it now relies almost entirely on its own AI models rather than exclusively on external Frontier models. 2.8 million patient contacts per week. The company now reports significant international adoption. According to Heidi, the platform is used in approximately 2.8 million patient interactions per week and is available in 190 countries and 110 languages. In total, the technology has already been used in more than 175 million patient interactions and has supported healthcare professionals during more than 67 million clinical work hours. The company has also grown rapidly from a financial standpoint. According to the company, annual recurring revenue (ARR) has risen from $1 million to $50 million as of April 2026 since the product's launch two years ago. DACH team to be doubled. Heidi plans to invest a portion of the capital specifically in Germany, Austria, and Switzerland. Since entering the market as part of the Series B funding round, the number of monthly active users in the DACH region had risen by 205 percent by August 2026. During this period, the company recorded more than 600,000 interactions with patients. Now, the company plans to double its workforce in the region. In Germany in particular, Heidi plans to build a local leadership team. The Swiss Medical Network is already among its customers in the region. Internationally, the platform is used in facilities in Australia and New Zealand, among other places. In the United Kingdom, Heidi reports that it was also selected as the sole provider for NHS England Midlands in a large-scale procurement of clinical AI documentation. Regulation becomes a factor. However, as integration into clinical workflows increases, so do the requirements for security, validation, and regulation. Heidi therefore plans to invest part of the funding in regulatory processes for advanced clinical functions in Europe and the UK. Clinical decisions will continue to rest with healthcare professionals. This brings Heidi to its next stage of development: evolving from a rapidly growing AI scribe into a more comprehensive infrastructure for clinical workflows. The $340 million provides the company with considerable financial flexibility to achieve this. The key question, however, will be whether the promised reduction in workload can be demonstrably combined with the high standards for data protection, security, and medical quality - even for more complex clinical functions.

Heidi lands $340 million to push healthcare AI beyond notetaking to action. By PYMNTS | September 22, 2026 Heidi raised $340 million in new funding to expand the capabilities of its AI Care Partner for clinicians and to support its growth, the company said in a Tuesday (Sept. 22) press release. The new funding includes a $100 million Series C funding round led by Blackbird and a $240 million growth investment led by General Catalyst's Customer Value Fund (CVF), according to the release. The funding round values Heidi at $900 billion, according to the release. The figure is up from the $465 billion valuation the company achieved in an October Series B funding round in which it raised $65 million. Heidi offers an AI Scribe that transcribes healthcare visits, Evidence that gives clinicians access to medical research at the point of care, Remote that captures audio and Dictate that provides voice-to-text capabilities, according to the release. Please add Mappedin to your preferred sources list so its news, data and interviews show up in your feed. Thanks! In the two years since Heidi launched its platform, the platform has supported over 175 million patient visits and more than 67 million clinical hours. The platform is being used in 190 countries and 110 languages, and the company's annual recurring revenue has reached $50 million, the release said. With the new funding, Heidi will deepen the platform's adoption within global health systems, add agentic capabilities that support the work around patient visits and continue to build the regulatory and clinical safety foundations for those capabilities, per the release. "From the day I started Heidi, the ambition was always bigger than writing doctor's notes," Heidi Co-Founder and CEO Dr. Thomas Kelly said in the release. "I imagined that AI would sit alongside clinicians and complete real work under their supervision. That's the shift we're now making, from documenting care to helping clinicians act on it." Pranav Singhvi, co-founder and partner at CVF, General Catalyst, said in the release that Heidi "has shown it can win trust inside the world's most complex health systems." Michael Tolo, general partner at Blackbird, said in the release that Heidi invested early in building its own models and training capability and has earned "the right to capture valuable downstream workflows in the most rigorous clinical settings globally." PYMNTS reported in April that there has been a proliferation of AI chatbots and virtual assistants in clinical settings. Examples include OpenEvidence's AI-powered medical search engine, OpenAI's ChatGPT for Clinicians and AWS's agentic AI solution that automates administrative tasks for healthcare professionals.